Stem Cell Transplant for Bone Marrow Failure Syndromes (NCT00176878) | Clinical Trial Compass
CompletedPhase 2/3
Stem Cell Transplant for Bone Marrow Failure Syndromes
United States10 participantsStarted 2000-06
Plain-language summary
The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord blood transplants in a safer manner by using less intensive therapy yet still achieve an acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure disorders.
Who can participate
Age range35 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients eligible for transplantation under this protocol will be \<35 years of age, and will be diagnosed with:
* a bone marrow failure syndrome unresponsive to available therapy, including but not limited to Diamond-Blackfan anemia, Shwachman Diamond syndrome or Kostmann's neutropenia but exclusive of aplastic anemia.
* Diamond Blackfan Anemia:
* Patients must show evidence of steroid resistance requiring equivalent of \>6 transfusions yearly despite steroid therapy.
* Evidence of developing aplasia or myelodysplasia will also be criteria for transplantation.
* Kostmann's Neutropenia, Shwachman-Diamond syndrome:
* Patients must have been previously diagnosed as having a clinical picture characteristic of Shwachman-Diamond syndrome (exocrine pancreatic insufficiency, growth retardation, metaphyseal dysostosis, neutropenia), or must have a bone marrow aspirate consistent with Kostmann's neutropenia, with no evidence of acute leukemia.
* Patients must have failed therapy with granulocyte-colony stimulating factor (G-CSF), as determined by an inability to maintain an absolute neutrophil count (ANC) \>750 cells/ml(3), or manifesting recurrent infections despite G-CSF administration resulting in life threatening infections or repeated hospitalizations (\<4 /year).
Exclusion Criteria:
* Patients \>35 years of age
* Karnofsky score \<70%
* Hepatic dysfunction as determined by bilirubin \>3.0, ALT \>150, or active hepatitis
* Pulmonary function …
What they're measuring
1
Number of Patients Alive (Survival) at 2 Years
Timeframe: 2 years
Trial details
NCT IDNCT00176878
SponsorMasonic Cancer Center, University of Minnesota